Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 174-182, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-928795
ABSTRACT
With the rapid development and wide application of next generation sequencing (NGS) technology, a series of researches have revealed that concurrent genetic alterations play an important role in the response and resistance of epidermal growth factor receptor (EGFR)-mutant NSCLC to EGFR-tyrosine kinase inhibitor (TKI). Besides, TP53 mutation is the most common co-mutation gene in EGFR-mutant NSCLC, which has been proved to confer a worse prognosis in EGFR-mutated patients treated with first, second and third generation of EGFR-TKIs. Currently, it is still being explored how to select the best treatment strategies for patients with concomitant presence of TP53 mutation in EGFR-mutant NSCLC. Here, we review the literature on recent research progress of TP53 concurrent mutation in EGFR-mutant advanced NSCLC.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Tumor Suppressor Protein p53
/
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
ErbB Receptors
/
Lung Neoplasms
/
Mutation
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS